RedHill Biopharma, a specialty biopharmaceutical company with a focus on developing treatments for the bacterial infection H. pylori, has renewed its contract with Medi-Cal, California's Medicaid healthcare program.
Under the agreement, H. pylori medication Talicia will not require prior authorization and will have a $0 copay for Medi-Cal patients, according to an Oct. 1 press release.
Talicia has been listed by Medi-Cal since 2021, making it available to 15 million Californian patients.